November 1, 2026 · Phase 2 readout
CRBP Phase 2 readout: a neutral outcome, +0.0%
On November 1, 2026, CRB-601 monoclonal antibody — Corbus Pharmaceuticals Holdings, Inc. (Solid Tumor) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved +0.0% in the window around the event. It had already run -31.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$4.22
1d before
$4.22
Event day
$3.91
1d after
$3.07
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+3.0% expected); the stock actually moved +0.0%. Model confidence at the time: 76%.
See the full scored track recordPre-catalyst setup
-31.2%
30-day run-up
5384%
30-day volatility
2.5×
volume spike
